Compare ADMA Biologics Inc (ADMA) vs PAGSEG Inc (PAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs PAGSEG Inc — how do they compare? ADMA Biologics Inc trades at $9.1 (market cap $2.13B), while PAGSEG Inc trades at $8.85 (market cap $2.49B). The key difference: PAGSEG Inc is the larger of the two by market cap, and PAGSEG Inc pays a 11.69% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PAGS | |
|---|---|---|
Market Cap | $2.13B | $2.49B |
Sector | Health | Technology |
52-Week High | $20.38 | $12.00 |
52-Week Low | $7.60 | $7.75 |
Enterprise Value | $2.20B | $10.12B |
Dividend Yield | — | 11.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
PAGS trades at $8.93, down 2.08% for the day, with a bearish technical signal from moving averages. The stock shows strong value fundamentals with a P/E of 6.32 and P/B of 0.89. Recent earnings were mixed, missing in Q1 2026 but beating in Q4 2025. The company maintains solid profitability with a 10.4% net income margin and generated positive net cash flow of $930 million in 2025. A dividend of $0.26 per share is scheduled for payment on June 1, 2026.
The investment outlook is supported by deep valuation discounts and analyst optimism, with 15 buy ratings. However, near-term headwinds include flat payment volume growth and pressure from Brazilian interest rates. The primary risk remains macroeconomic sensitivity in Brazil, while the opportunity lies in potential expansion of banking and credit operations driving future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
